Replies to post #54910 on Biotech Values

[ghmm]

For what its worth United had Phase 2 Data of OvaRex presented at ASCO in combination with Chemo (for Front-line Ovarian Cancer) and prior phase 2 work in recurrent ovarian cancer in combination with chemo both showing a synergistic immune response.

I am more negative then positive on the Phase 3 IMPACT studies (watchful waiting period administration of OvaRex). I think the data gathered thus far may lead to further studies in using immuno-therapy in conjunction with chemotherapy. It seems a bit counterintuitive to me but perhaps there is more to it if several companies are discovering similar results.

[DrBengtP]

Thanks for your answer and for directing me to Dr. Petrylak's presentation - I hadn't seen it before.

It really looks like there is synergy between docetaxel and Provenge, but I'm not quite sure what to read from the KM graph showing the survival of the 51+31=82 patients in D9901+D9902A who received docetaxel. Thus, considering the timing of the Provenge studies and the timing of the docetaxel approval, it seems impossible that anyone could have received docetaxel (and died after being on a Provenge study for only 6-9 months (the approximate time for the first death on the KM curve). So what is it actually that is shown on the graph? Is there an obvious answer that I missed?

Basically, I try to piece together a coherrent picture of what the data are, and such a discrepancy-look-alike like the one I mentioned above - while perhaps not obviously crucial - may still be interesting.

Thanks!
B.